

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Medical technologies evaluation programme

### Equality impact assessment: Guidance development

#### MT471 VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

#### Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

People who are older or physically disabled are more likely to have chronic and complex wounds. People with certain family origins (South Asian, Chinese, black African and African-Caribbean family origins) are more prone to poor wound healing because of their increased risk of diabetes. Age, disability, and race are protected characteristics. The committee considerations surrounding these equality considerations can be found in section 4.7 of the draft guidance.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No further equality issues were highlighted in the sponsor's submission or patient organisation questionnaires.

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

The committee heard that people with serious mental health or cognitive impairment may have difficulty keeping the system in place. This is stated in section 4.7 of the draft guidance.

**4.** Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No.

**5.** Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

**6.** Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

**7.** Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

The committee considerations surrounding this equality consideration can be found in section 4.7 of the draft guidance.

**Approved by Associate Director:** Joanne Holden

**Date:** 23 September 2020

## Medical technology guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional potential equality issues have been raised during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations have not changed as a result of consultation.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations have not changed as a result of consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations have not changed as a result of consultation.

5. Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

Yes. Section 4.8 of the guidance describes the committee's discussions and conclusions around the equality considerations.

**Approved by Programme Director:** Chris Chesters (deputising for AD sign off)

**Date:** 02/12/2020